TSXV - Delayed Quote CAD

Rakovina Therapeutics Inc. (RKV.V)

0.0450

0.0000

(0.00%)

At close: April 17 at 12:49:05 PM EDT

When Will Rakovina Therapeutics Inc. (CVE:RKV) Turn A Profit?

With the business potentially at an important milestone, we thought we'd take a closer look at Rakovina Therapeutics...

Simply Wall St. 16 days ago

RKVTF
Rakovina Therapeutics Unveils Preclinical Data at the AACR - World’s Premier Cancer Research Forum

Cutting-Edge Research Results Showcase AI-Powered Drug DiscoveryVANCOUVER, British Columbia, March 25, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, today announced that two of its abstracts have been accepted for presentation at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25–30 in Ch

GlobeNewswire 24 days ago

RKVTF
Rakovina's AI-driven Anti-Cancer Compounds in Pre-clinical Testing

Rakovina Therapeutics (RKV.V) on Wednesday said it received the first synthesized batch of AI-genera

PREMIUM
MT Newswires last month

RKVTF
Next-Gen Cancer Treatment: Rakovina’s AI-Driven ATR Inhibitors Enter Preclinical Testing

Harnessing generative AI to develop targeted therapies for DNA damage response, including hard-to-treat central nervous system malignanciesVANCOUVER, British Columbia, March 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV)(FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, announced today that the company has received the first synthesized batch of AI-generated ATR inhibitor compounds devel

GlobeNewswire last month

RKVTF
Rakovina Therapeutics and Variational AI Strengthen Partnership

Strategic Funding Led by Nimbus Synergies, Backed by Merck GHI, to Accelerate AI-Powered CollaborationsVANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response technologies, proudly reaffirms its strategic partnership with Variational AI. This announcement comes on the heels of Variational AI’s impressive $5.5 million oversubscribed financing round, led by

GlobeNewswire last month

RKVTF
Rakovina Synthesizes Additional Compounds in AI-Driven Cancer Drug Discovery Program

Rakovina Therapeutics (RKV.V) on Thursday said it is advancing its AI-driven drug discovery program.

PREMIUM
MT Newswires 2 months ago

RKVTF
Rakovina Therapeutics Announces Additional Synthesized Compounds in its AI-Driven Cancer Drug Discovery Program

VANCOUVER, British Columbia, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response technologies, announces continued advancement of its AI-driven drug discovery program. Over the next four months, additional small-molecule drug candidates, designed in collaboration with Pharma Inventor Inc., will be synthesized and delivered for further evaluation. The expanded program builds on th

GlobeNewswire 2 months ago

RKVTF
Rakovina Therapeutics Announces Listing on Frankfurt Stock Exchange

VANCOUVER, British Columbia, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce that its common shares are now listed on the Frankfurt Stock Exchange (FSE) under the ticker symbol “7J0”. This strategic milestone marks Rakovina Therapeutics’ entry into one of the largest equity markets in Europe, providing increased visibility and

GlobeNewswire 2 months ago

RKVTF
Rakovina Therapeutics to Participate in BioInnovate UBC Annual Conference

VANCOUVER, British Columbia, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, today announced its participation in the BioInnovate UBC Annual Conference on February 1, 2025. This premier event, hosted at the University of British Columbia (UBC), unites academic researchers, biotech innovators, and industry professionals to foster collaboration a

GlobeNewswire 2 months ago

RKVTF
Rakovina Therapeutics Comments on $500 Billion AI Infrastructure Investment and Its Implications for Healthcare Innovation

VANCOUVER, British Columbia, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company at the forefront of AI-driven drug discovery, yesterday commented on the announcement of a $500 billion private-sector investment into AI infrastructure by OpenAI, SoftBank, and Oracle through their joint venture, Stargate. This historic initiative marks a defining moment for the AI and healthcare sectors, setting the stage for transformative advancements in precisi

GlobeNewswire 2 months ago

RKVTF
Rakovina Therapeutics Up as Announces "Key Milestone" In Cancer Drug Innovation

Rakovina Therapeutics (RKV.V) was up, but off day highs at last look on Monday after announcing a s

PREMIUM
MT Newswires 3 months ago

RKVTF
Rakovina Therapeutics Announces Key Milestone in Cancer Drug Innovation in Collaboration with Variational AI

ATR-Targeted Molecules Designed for CNS Penetration Set the Stage for Next-Generation TreatmentsVANCOUVER, British Columbia, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce the successful achievement of a shortlist of AI-generated molecules targeting ATR (Ataxia Telangiectasia and Rad3-related protein) with specific designs for

GlobeNewswire 3 months ago

RKVTF
Rakovina Therapeutics Announces Receipt of AI-Derived Drug Candidates and Advancement to Preclinical Validation

VANCOUVER, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company focused on the development of new cancer therapies based on novel DNA-damage response technologies, announces the successful synthesis of novel small-molecule drug candidates designed under the Company’s artificial intelligence (AI) platform collaboration. The initial batch of compounds have arrived at Rakovina’s state-of-the-art wet-lab facility at the University o

GlobeNewswire 3 months ago

RKVTF
Rakovina Therapeutics to Connect with Industry Leaders During 43rd Annual J.P. Morgan Healthcare Conference Week

VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics, Inc. (TSX: RKV), a biopharmaceutical company focused on the development of new cancer therapies based on novel DNA-damage response technologies, is pleased to announce its participation in events and meetings being held alongside the 43rd Annual J.P. Morgan Healthcare Conference, taking place January 13-16, 2025, in San Francisco. Showcasing Innovation on a Global Stage As the premier healthcare investment symp

GlobeNewswire 3 months ago

RKVTF
Rakovina Therapeutics: Reflecting on 2024 Success and Building Momentum for a Transformative 2025

VANCOUVER, British Columbia, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) a biopharmaceutical company focused on the development of new cancer therapies based on novel DNA-damage response technologies, is pleased to provide a corporate update summarizing its achievements in 2024 and outline corporate objectives for 2025. Strategic Pivot to AI-Driven Drug Discovery In March 2024, Rakovina unveiled a strategic shift toward the use of AI-dr

GlobeNewswire 3 months ago

RKVTF
Rakovina Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations

VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) announces that in accordance with the terms of an indenture entered into between the Company and Odyssey Trust Company (“Odyssey”) dated May 29, 2023 (the “Indenture”), certain holders (each, a “Debentureholder”) of 12.0% unsecured convertible debentures of the Company (the “Debentures”) have elected to receive common shares of the Company (the “Common Shares”) in

GlobeNewswire 3 months ago

RKVTF
Rakovina Therapeutics Announces Closing of Oversubscribed $3M Private Placement

VANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”, “Rakovina”, or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce the closing of a $3.0 million private placement. The private placement consists of 50,000,000 units (the “Units”) at a price of $0.06 per Unit. Each Unit consists of one common share of the Company (

GlobeNewswire 4 months ago

RKVTF
Rakovina Therapeutics Increased Private Placement Offering to C$3 Million; Flags Upcoming Presentation

Rakovina Therapeutics (RKV.V), a biopharmaceutical company, overnight Monday said it increased its p

PREMIUM
MT Newswires 4 months ago

RKVTF
Rakovina Therapeutics Announces Presentation at the 13th Annual Tumour Models London Summit

VANCOUVER, British Columbia, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response targeting technologies, is pleased to announce participation at the 13th Annual Tumour Models Summit. The Company’s president and chief scientific officer, Prof. Mads Daugaard, has been invited as an expert speaker at the event, which will take place December

GlobeNewswire 4 months ago

RKVTF
Rakovina Therapeutics Increases Private Placement Offering to $3.0 Million

VANCOUVER, British Columbia, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce that its previously announced private placement has been further upsized up to $3 million, based on strong indications of interest from potential investors in the financing. The Offering is structured as units pr

GlobeNewswire 4 months ago

RKVTF

Performance Overview

Return	RKV.V	S&P/TSX Composite index (^GSPTSE)
YTD	-76.32%	-1.74%
1-Year	-50.00%	+11.71%
3-Year	-75.00%	+10.69%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Rakovina Therapeutics Inc. (RKV.V)

When Will Rakovina Therapeutics Inc. (CVE:RKV) Turn A Profit?

Rakovina Therapeutics Unveils Preclinical Data at the AACR - World’s Premier Cancer Research Forum

Rakovina's AI-driven Anti-Cancer Compounds in Pre-clinical Testing

Next-Gen Cancer Treatment: Rakovina’s AI-Driven ATR Inhibitors Enter Preclinical Testing

Rakovina Therapeutics and Variational AI Strengthen Partnership

Rakovina Synthesizes Additional Compounds in AI-Driven Cancer Drug Discovery Program

Rakovina Therapeutics Announces Additional Synthesized Compounds in its AI-Driven Cancer Drug Discovery Program

Rakovina Therapeutics Announces Listing on Frankfurt Stock Exchange

Rakovina Therapeutics to Participate in BioInnovate UBC Annual Conference

Rakovina Therapeutics Comments on $500 Billion AI Infrastructure Investment and Its Implications for Healthcare Innovation

Rakovina Therapeutics Up as Announces "Key Milestone" In Cancer Drug Innovation

Rakovina Therapeutics Announces Key Milestone in Cancer Drug Innovation in Collaboration with Variational AI

Rakovina Therapeutics Announces Receipt of AI-Derived Drug Candidates and Advancement to Preclinical Validation

Rakovina Therapeutics to Connect with Industry Leaders During 43rd Annual J.P. Morgan Healthcare Conference Week

Rakovina Therapeutics: Reflecting on 2024 Success and Building Momentum for a Transformative 2025

Rakovina Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations

Rakovina Therapeutics Announces Closing of Oversubscribed $3M Private Placement

Rakovina Therapeutics Increased Private Placement Offering to C$3 Million; Flags Upcoming Presentation

Rakovina Therapeutics Announces Presentation at the 13th Annual Tumour Models London Summit

Rakovina Therapeutics Increases Private Placement Offering to $3.0 Million

Performance Overview